Rosacea Treatment Market Size, Share & Trends Analysis Report By Drug Class (Alpha Agonists, Antibiotics, Retinoids, Corticosteroids), By Mode of Administration (Topical, Oral), By Region, And Segment Forecasts, 2019 - 2025

Published: Jan, 2019 | Pages: 83 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global rosacea treatment market size is expected to reach USD 2.6 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 6.8% over the forecast period. Several factors such as an advanced formulations and high prevalence of the disease are forecasted to fuel the market growth.

Rosacea affects more than 400 million people worldwide and the global incidence among adults is estimated at 5%. Less than 1.5 million patients seek treatment, making it a highly underdiagnosed condition. This disease has a higher incidence in women than men, with several studies claiming a possible association between rosacea and menopause. In the absence of an absolute cure, treatment options are largely focused on management of the disease.

The market for rosacea treatment is majorly genericized due to multiple patent expiries, leading to a highly fragmented therapeutic landscape. Rosacea is an underdiagnosed condition and is frequently misdiagnosed as acne. Off-label use of therapeutics pose an intensely competitive space for rosacea-specific treatments.

Topical therapies remain the mainstay for treatment. Topical products captured more than 60% market share in 2017. Although topical items are expected to maintain their lead over oral medicines through the forecast period, the market is witnessing a paradigm shift supported by the increasing inclination towards combination products.

Therapeutic options available for rosacea treatment are antibiotics, alpha agonists, retinoids, immunosuppressants, corticosteroids, antihypertensive agents, and others. Antibiotics are prescribed for the first-line treatment, making them the dominant drug class in 2017-a trend expected to continue through 2025.

The rosacea treatment market growth is supported by strong commercial sales from key products such as Rhofade, Mirvaso, Oracea, MetroGel, Noritate, and Finacea. Although increased penetration of generic drugs is a constraining factor, the impending launch of several promising pipeline products indicate an optimistic future for the global market.

Further key findings from the report suggest:

• The topical drugs segment held over 65% market share in 2017. These drugs are generally prescribed as first-line treatments and are preferred over other options in terms of convenience and results

• Alpha agonists is anticipated to be the fastest growing drug class, with a CAGR of over 8% during the forecast period

• Geographically, North America and Europe are the leading regions as the disease tends to affect people with fair/light skin. Asia Pacific is anticipated to witness the fastest growth owing to improved economic and healthcare scenario

• Key players operating in the rosacea treatment market include Bayer Schering AG; Bausch Health Companies Inc.; Foamix Pharmaceuticals; Nestle S.A.; and Allergan Plc.

 Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Research Methodology
                   1.2 Research Scope and Assumptions
                   1.3 List of Tables

Chapter 2 Executive Summary
                   2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope
                   3.1 Market Segmentation

Chapter 4 Market Definitions
                   4.1 Disease Primer and Epidemiology
                   4.2 Market Segmentation

Chapter 5 Industry Outlook
                   5.1 Market Driver Analysis
                       5.1.1 Surging geriatric population
                       5.1.2 Advanced formulations of drugs
                       5.1.3 Shift towards combination therapies
                       5.1.4 Increase in disease prevalence
                   5.2 Market Restraint Analysis
                       5.2.1 Generic penetration
                       5.2.2 Off-label usage of drugs

Chapter 6 Business Environment Analysis
                   6.1 SWOT Analysis; By factor (political & legal, economic and technological)
                   6.2 Porter's Five Forces Analysis
                   6.3 Pipeline Analysis

Chapter 7 Drug Class Business Analysis
                   7.1 Rosacea Treatment market: Drug Class Movement Analysis
                   7.2 Antibiotics
                       7.2.1 Antibiotics market estimates and forecast, 2014 - 2025
                   7.3 Alpha Agonists
                       7.3.1 Alpha agonists market estimates and forecast, 2014 - 2025
                   7.4 Retinoids
                       7.4.1 Retinoids market estimates and forecast, 2014 - 2025
                   7.5 Corticosteroids
                       7.5.1 Corticosteroids market estimates and forecast, 2014 - 2025
                   7.6 Immunosuppressants
                       7.6.1 Immunosuppressants market estimates and forecast, 2014 - 2025
                   7.7 Antihypertensive Agents
                       7.7.1 Antihypertensive agents market estimates and forecast, 2014 - 2025
                   7.8 Others
                       7.8.1 Others market estimates and forecast, 2014 - 2025

Chapter 8 Mode Of Administration Business Analysis
                   8.1 Rosacea Treatment market: Mode of Administration Movement Analysis
                   8.2 Topical
                       8.2.1 Topical market estimates and forecast, 2014 - 2025
                   8.3 Oral
                       8.3.1 Oral market estimates and forecast, 2014 - 2025

Chapter 9 Regional Business Analysis
                   9.1 Rosacea Treatment Market: Regional Movement Analysis
                   9.2 North America
                       9.2.1 North America market estimates and forecast, 2014 - 2025
                       9.2.2 U.S.
                           9.2.2.1 U.S. market estimates and forecast, 2014 - 2025
                       9.2.3 Canada
                           9.2.3.1 Canada market estimates and forecast, 2014 - 2025
                   9.3 Europe
                       9.3.1 Europe market estimates and forecast, 2014 - 2025
                       9.3.2 Germany
                       9.3.3 Germany market estimates and forecast, 2014 - 2025
                       9.3.4 U.K.
                       9.3.5 U.K. market estimates and forecast, 2014 - 2025
                   9.4 Asia-Pacific
                       9.4.1 Asia-Pacific market estimates and forecast, 2014 - 2025
                       9.4.2 Japan
                           9.4.2.1 Japan market estimates and forecast, 2014 - 2025
                       9.4.3 China
                           9.4.3.1 China market estimates and forecast, 2014 - 2025
                       9.4.4 India
                           9.4.4.1 India market estimates and forecast, 2014 - 2025
                   9.5 Latin America
                       9.5.1 Latin America market estimates and forecast, 2014 - 2025
                       9.5.2 Brazil
                           9.5.2.1 Brazil market estimates and forecast, 2014 - 2025
                       9.5.3 Mexico
                           9.5.3.1 Market estimates and forecast, 2014 - 2025
                   9.6 Middle East and Africa
                       9.6.1 Middle-East and Africa market estimates and forecast, 2014 - 2025
                       9.6.2 South Africa
                       9.6.3 South Africa market estimates and forecast, 2014 - 2025

Chapter 10 Company Profile
                   10.1 Company Profiles
                       10.1.1 Nestle S.A.
                           10.1.1.1 Company Overview
                           10.1.1.2 Financial Performance
                           10.1.1.3 Product Benchmarking
                           10.1.1.4 Strategic Initiatives
                       10.1.2 Allergan Plc
                           10.1.2.1 Company Overview
                           10.1.2.2 Financial Performance
                           10.1.2.3 Product Benchmarking
                           10.1.2.4 Strategic Initiatives
                       10.1.3 Bayer Schering AG
                           10.1.3.1 Company Overview
                           10.1.3.2 Financial Performance
                           10.1.3.3 Product Benchmarking
                           10.1.3.4 Strategic Initiatives
                       10.1.4 Bausch Health Companies Inc.
                           10.1.4.1 Company Overview
                           10.1.4.2 Financial Performance
                           10.1.4.3 Product Benchmarking
                           10.1.4.4 Strategic Initiatives
                       10.1.5 Foamix Pharmaceuticals
                           10.1.5.1 Company Overview
                           10.1.5.2 Financial Performance
                           10.1.5.3 Product Benchmarking
                           10.1.5.4 Strategic Initiatives
                       10.1.6 Sol-Gel Technologies
                           10.1.6.1 Company Overview
                           10.1.6.2 Financial Performance
                           10.1.6.3 Product Benchmarking
                           10.1.6.4 Strategic Initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 Rosacea Epidemiology - 2017
Table 3 Rosacea - Pipeline Intelligence
Table 4 North America Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 5 North America Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 6 U.S. Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 7 U.S. Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 8 Canada Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 9 Canada Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 10 Europe Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 11 Europe Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 12 U.K. Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 13 U.K. Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 14 Germany Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 15 Germany Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 16 Latin America Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 17 Latin America Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 18 Brazil Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 19 Brazil Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 20 Mexico Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 21 Mexico Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 22 Asia Pacific Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 23 Asia Pacific Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 24 Japan Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 25 Japan Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 26 China Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 27 China Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 28 India Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 29 India Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 30 MEA Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 31 MEA Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)
Table 32 South Rosacea Market, by Drug Class, 2014 - 2025 (USD Million)
Table 33 South Africa Rosacea Market, by Mode of Administration, 2014 - 2025 (USD Million)

List of Figures

Fig.1 Rosacea treatment market snapshot
Fig.2 Rosacea treatment drugs market segmentation
Fig.3 Current disease prevalence - 2017
Fig.4 Rosacea treatment market - driver impact
Fig.5 Rosacea treatment market - restraint impact 
Fig.6 SWOT analysis, by factor (political & legal, economic and technological)
Fig.7 Porter's five forces analysis
Fig.8 Rosacea treatment market: Drug class outlook and key takeaways
Fig.9 Rosacea treatment market: Drug class movement analysis
Fig.10 Amtibiotics market estimates and forecast, 2014 - 2025 (USD Million)
Fig.11 Antibiotics market estimates and forecast, 2014 - 2025 (USD Million)
Fig.12 Alpha agonists market estimates and forecast, 2014 - 2025 (USD Million)
Fig.13 Retinoids market estimates and forecast, 2014 - 2025 (USD Million)
Fig.14 Corticosteroids market estimates and forecast, 2014 - 2025 (USD Million)
Fig.15 Immunosuppressants market estimates and forecast, 2014 - 2025 (USD Million)
Fig.16 Antihypertensive agents market estimates and forecast, 2014 - 2025 (USD Million)
Fig.17 Others market estimates and forecast, 2014 - 2025 (USD Million)
Fig.18 Rosacea treatment market: Mode of administration outlook and key takeaways
Fig.19 Rosacea treatment market: Mode of administration movement analysis
Fig.20 Topical market estimates and forecast, 2014 - 2025 (USD Million)
Fig.21 Oral market estimates and forecast, 2014 - 2025 (USD Million)
Fig.22 Rosacea Treatment Market: Regional Outlook and Key Takeaways
Fig.23 Rosacea Treatment market: Regional movement analysis
Fig.24 North America
Fig.25 North America. market estimates and forecast, 2014 - 2025 (USD Million)
Fig.26 U.S. market estimates and forecast, 2014 - 2025 (USD Million)
Fig.27 Canada market estimates and forecast, 2014 - 2025 (USD Million)
Fig.28 Europe
Fig.29 Europe market estimates and forecast, 2014 - 2025 (USD Million)
Fig.30 Germany market estimates and forecast, 2014 - 2025 (USD Million)
Fig.31 U.K. market estimates and forecast, 2014 - 2025 (USD Million)
Fig.32 Asia-Pacific
Fig.33 Asia-Pacific market estimates and forecast, 2014 - 2025 (USD Million)
Fig.34 Japan market estimates and forecast, 2014 - 2025 (USD Million)
Fig.35 China market estimates and forecast, 2014 - 2025 (USD Million)
Fig.36 India market estimates and forecast, 2014 - 2025 (USD Million)
Fig.37 Latin America
Fig.38 Latin America market estimates and forecast, 2014 - 2025 (USD Million)
Fig.39 Brazil market estimates and forecast, 2014 - 2025 (USD Million)
Fig.40 Mexico market estimates and forecast, 2014 - 2025 (USD Million)
Fig.41 Middle East & Africa
Fig.42 MEA market estimates and forecast, 2014 - 2025 (USD Million)
Fig.43 South Africa market estimates and forecast, 2014 - 2025 (USD Million)
Fig.44 Company profile